Clinical Practice Guidelines for the Management of Congenital Cytomegalovirus Infection in Japan 2023: Executive Summary.
Yoshinori ItoIchiro MoriokaNaoto TakahashiKazumichi FujiokaKiyonori MiuraHiroyuki MoriuchiNoriko MorimotoTetsushi YoshikawaMariko AshinaShinya AbeHitomi ImafukuAkiko UchidaAya OkahashiSatsuki KakiuchiYu KakimotoSoichiro KawataYoshiki KawamuraTakumi KidoHiroyuki KidokoroKei KozawaTomohiro SamejimaTakako SuzukiKenji TanimuraChiharu TomonagaYuka ToriiMegumi NakanishiNobuhiko NaganoTakeshi NagamatsuHajime NaritaKoji NishimuraNorie NonobeYuri HasegawaKoichiro HaraMidori HijikataTakuya FukudaYusuke FunatoNobuko MimuraNobuko YamamotoAi YoshitomiYasumasa KakeiTomoyuki KodamaAkira OkaPublished in: The Pediatric infectious disease journal (2024)
Congenital cytomegalovirus (cCMV) infection is the most common congenital infection in developed countries. Although a standard therapy has not yet been established, evidence for the management of cCMV infection has been accumulating. The first edition of the "Clinical Practice Guidelines for the Management of Congenital Cytomegalovirus Infection" was published in Japan in 2023. This summary outlines the clinical questions (CQs) in the guidelines, with reference to the Japanese Medical Information Distribution Service Manual. Overall, 20 CQs with statements regarding prenatal risk assessment, prevention and management at diagnosis (CQs 1-1-1-3), diagnosis (CQs 2-1-2-6), treatment (CQs 3-1-3-7) and follow-up requirements (CQs 4-1-4-4) have been discussed. For each statement, the levels of recommendation, evidence and consensus rates were determined. These guidelines will assist in the management of patients with cCMV infection.